IGH/MAFB Translocation, Dual Fusion Probe

The t(14;20) translocation, present in around 2% of Multiple Myeloma cases is one of seven recurrent IGH translocations that are referred to as primary oncogenic events in Multiple Myeloma cases. These translocations result in a transcription product that dysregulates further controlling genes such as the cyclin family of cell cycle control genes which then disrupts normal cell division. As a result of the translocation the transcription of the IGH-MAFB fusion product is up-regulated which has been shown to cause overexpression of Cyclin D3 in around 7% of tumours. Know more at: http://www.creative-bioarray.com/IGH-MAFB-Translocation,-Dual-Fusion-Probe-FHPC-067-item-4708.htm